Dr. Roth specializes in comparative effectiveness research (CER) methods, including: observational study design, decision-analytic modeling, systematic review, meta-analysis, and generalized linear modeling. His research interests involve the application of CER methods to evaluate the benefit-risk tradeoffs and value of pharmaceutical and diagnostic technologies in cancer, with specific focus on pharmacogenomic testing applications, cancer screening strategies, and alternative treatment options in lung, breast, and prostate cancer. He received his MHA from the University of Washington Department of Health Services and a PhD in Pharmaceutical Outcomes Research and Policy from the University of Washington.